Unresectable Stage III NSCLC Should Not be Treated With Neoadjuvant Therapy and Re-Evaluated for Resection

By sjmartinez • August 21, 2023

Moghanaki D, Lisberg A, Oh S, Lee JM. Unresectable Stage III NSCLC Should Not be Treated With Neoadjuvant Therapy and Re-Evaluated for Resection. J Thorac Oncol. 2023 Sep;18(9):1129-1133. doi: 10.1016/j.jtho.2023.06.005. PMID: 37599046.

Tags: Hematology/Oncology, Publications, Pulmonary, Critical Care & Sleep Medicine, Veterans Administration

Real-World Multicenter Study of PD-1 Blockade in HIV-Associated Classical Hodgkin Lymphoma Across the United States

Lurain K, Zarif TE, Ramaswami R, Nassar AH, Adib E, Abdel-Wahab N, Chintapally N, Drolen CE, Feldman T, Haykal T, Nebhan CA, Kambhampati S, Li[...]

Antibody Drug Conjugate Sacituzumab Govitecan Enables A Sequential TOP1/PARP Inhibitor Cancer Therapy Strategy in Breast Cancer Patients

Bardia A, Sun S, Thimmiah N, Coates JT, Wu B, Abelman RO, Spring L, Moy B, Ryan P, Melkonyan MN, Partridge A, Juric D, Peppercorn[...]

Navigating Complexity: A Case Study on Hemophagocytic Lymphohistiocytosis Diagnosis and Management Challenges

Nguyen J, Tun N, Burley N, Bolos D. Navigating Complexity: A Case Study on Hemophagocytic Lymphohistiocytosis Diagnosis and Management Challenges. Cureus. 2024 May 4;16(5):e59628. doi:[...]